Modeling interactions between leukemia-specific chromosomal changes, somatic mutations, and gene expression patterns during progression of core-binding factor leukemias

Genes Chromosomes and Cancer

Volumn 49, Issue 2, 2010, Pages 182-191

  Jones, Dan ^a   Yao, Hui ^a   Romans, Angela ^a   Dando, Caroline ^b   Pierce, Sherry ^a   Borthakur, Gautam ^a   Hamilton, Amy ^b   Bueso Ramos, Carlos ^a   Ravandi, Farhad ^a   Garcia Manero, Guillermo ^a   Kantarjian, Hagop ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b FLUIDIGM CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AURORA A KINASE; AURORA B KINASE; CHECKPOINT KINASE 1;

ACUTE GRANULOCYTIC LEUKEMIA; ANEUPLOIDY; ARTICLE; CANCER CLASSIFICATION; CANCER GROWTH; CANCER RELAPSE; CHROMOSOME BAND; CONTROLLED STUDY; CYTOGENETICS; DNA REPLICATION; GENE EXPRESSION; GENE INTERACTION; HUMAN; KARYOTYPING; MAJOR CLINICAL STUDY; ONCOGENE RAS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; SOMATIC MUTATION;

BONE MARROW CELLS; CHROMOSOMES, HUMAN; CHROMOSOMES, HUMAN, PAIR 16; CHROMOSOMES, HUMAN, PAIR 21; CHROMOSOMES, HUMAN, PAIR 8; CORE BINDING FACTOR ALPHA 2 SUBUNIT; CORE BINDING FACTORS; DISEASE PROGRESSION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KARYOTYPING; LEUKEMIA, MYELOID, ACUTE; MUTATION; RECURRENCE; TRANSLOCATION, GENETIC;

EID: 75149119465     PISSN: 10452257     EISSN: 10982264     Source Type: Journal    
DOI: 10.1002/gcc.20732     Document Type: Article

References (37)

1. Andreeff M, Ruvolo V, Gadgil S, Zeng C, Coombes K, Chen W, Kornblau S, Baron AE, Drabkin HA. 2008. HOX expression patterns identify a common signature for favorable AML. Leukemia 22:2041-2047.
2. Appelbaum FR, Kopecky KJ, Tallman MS, Slovak ML, Gundacker HM, Kim HT, Dewald GW, Kantarjian HM, Pierce, Estey EH. 2006. The clinical spectrum of adult acute myeloid leukaemia associated with core binding factor translocations. Br J Haematol 135:165-173.
3. Boissel N, Leroy H, Brethon B, Philippe N, de Botton S, Auvrignon A, Raffoux E, Leblanc T, Thomas X, Hermine O, Quesnel B, Baruchel A, Leverger G, Dombret H, Preudhomme C. 2006. Incidence and prognostic impact of c-Kit, FLT3, and Ras gene mutations in core binding factor acute myeloid leukemia (CBF-AML). Leukemia 20:965-970.
4. Boyapati A, Yan M, Peterson LF, Biggs JR, Le Beau MM, Zhang DE. 2007. A leukemia fusion protein attenuates the spindle checkpoint and promotes aneuploidy. Blood 109:3963-3971.
5. Bullinger L, Rucker FG, Kurz S, Du J, Scholl C, Sander S, Corbacioglu A, Lottaz C, Krauter J, Frohling S, Ganser A, Schlenk RF, Dohner K, Pollack JR, Dohner H. 2007. Gene-expression profiling identifies distinct subclasses of core binding factor acute myeloid leukemia. Blood 110:1291-1300.
6. Cairoli R, Beghini A, Grillo G, Nadali G, Elice F, Ripamonti CB, Colapietro P, Nichelatti M, Pezzetti L, Lunghi M, Cuneo A, Viola A, Ferrara F, Lazzarino M, Rodeghiero F, Pizzolo G, Larizza L, Morra E. 2006. Prognostic impact of c-KIT mutations in core binding factor leukemias: An Italian retrospective study. Blood 107:3463-3468.
7. Care RS, Valk PJ, Goodeve AC, Abu-Duhier FM, Geertsma-Kleinekoort WM, Wilson GA, Gari MA, Peake IR, Lowenberg B, Reilly JT. 2003. Incidence and prognosis of c-KIT and FLT3 mutations in core binding factor (CBF) acute myeloid leukaemias. Br J Haematol 121:775-777.
8. Delaunay J, Vey N, Leblanc T, Fenaux P, Rigal-Huguet F, Witz F, Lamy T, Auvrignon A, Blaise D, Pigneux A, Mugneret F, Bastard C, Dastugue N, Van den Akker J, Fiere D, Reiffers J, Castaigne S, Leverger G, Harousseau JL, Dombret H. 2003. Prognosis of inv(16)/t(16;16) acute myeloid leukemia (AML): A survey of 110 cases from the French AML Intergroup. Blood 102:462-469.
9. Dombret H, Preudhomme C, Boissel N. 2009. Core binding factor acute myeloid leukemia (CBF-AML): Is high-dose Ara-C (HDAC) consolidation as effective as you think? Curr Opin Hematol 16:92-97.
10. Goemans BF, Zwaan CM, Miller M, Zimmermann M, Harlow A, Meshinchi S, Loonen AH, Hahlen K, Reinhardt D, Creutzig U, Kaspers GJ, Heinrich MC. 2005. Mutations in KIT and RAS are frequent events in pediatric core-binding factor acute myeloid leukemia. Leukemia 19:1536-1542.
11. Grubach L, Juhl-Christensen C, Rethmeier A, Olesen LH, Aggerholm A, Hokland P, Ostergaard M. 2008. Gene expression pro.ling of Polycomb, Hox and Meis genes in patients with acute myeloid leukaemia. Eur J Haematol 81:112-122.
12. Gustafson SA, Lin P, Chen SS, Chen L, Abruzzo LV, Luthra R, Medeiros LJ, Wang SA. 2009. Therapy-related acute myeloid leukemia with t(8;21) (q22;q22) shares many features with de novo acute myeloid leukemia with t(8;21)(q22;q22) but does not have a favorable outcome. Am J Clin Pathol 131:647-655.
13. Huang L, Abruzzo LV, Valbuena JR, Medeiros LJ, Lin P. 2006. Acute myeloid leukemia associated with variant t(8;21) detected by conventional cytogenetic and molecular studies: A report of four cases and review of the literature. Am J Clin Pathol 125:267-272.
14. Jongen-Lavrencic M, Sun SM, Dijkstra MK, Valk PJ, Lowenberg B. 2008. MicroRNA expression profiling in relation to the genetic heterogeneity of acute myeloid leukemia. Blood 111:5078-5085.
15. Kim HG, Kojima K, Swindle CS, Cotta CV, Huo Y, Reddy V, Klug CA. 2008. FLT3-ITD cooperates with inv(16) to promote progression to acute myeloid leukemia. Blood 111:1567-1574.
16. Z, Lu J, Sun M, Mi S, Zhang H, Luo RT, Chen P, Wang Y, Yan M, Qian Z, Neilly MB, Jin J, Zhang Y, Bohlander SK, Zhang DE, Larson RA, Le Beau MM, Thirman MJ, Golub TR, Rowley JD, Chen J. 2008. Distinct microRNA expression profiles in acute myeloid leukemia with common translocations. Proc Natl Acad Sci USA 105:15535-15540.
17. Lin P, Jones D, Medeiros LJ, Chen W, Vega-Vazquez F, Luthra R. 2006. Activating FLT3 mutations are detectable in chronic and blast phase of chronic myeloproliferative disorders other than chronic myeloid leukemia. Am J Clin Pathol 126:530-533.
18. Lorsbach RB, Downing JR. 2001. The role of the AML1 transcription factor in leukemogenesis. Int J Hematol 74:258-265.
19. Marcucci G, Mrozek K, Ruppert AS, Maharry K, Kolitz JE, Moore JO, Mayer RJ, Pettenati MJ, Powell BL, Edwards CG, Sterling LJ, Vardiman JW, Schiffer CA, Carroll AJ, Larson RA, Bloomfield CD. 2005. Prognostic factors and outcome of core binding factor acute myeloid leukemia patients with t(8;21) differ from those of patients with inv(16): A Cancer and Leukemia Group B study. J Clin Oncol 23:5705-5717.
20. Meshinchi S, Stirewalt DL, Alonzo TA, Zhang Q, Sweetser DA, Woods WG, Bernstein ID, Arceci RJ, Radich JP. 2003. Activating mutations of RTK/ras signal transduction pathway in pediatric acute myeloid leukemia. Blood 102:1474-1479.
21. Mrozek K, Marcucci G, Paschka P, Bloomfield CD. 2008. Advances in molecular genetics and treatment of core-binding factor acute myeloid leukemia. Curr Opin Oncol 20:711-718.
22. Nguyen S, Leblanc T, Fenaux P, Witz F, Blaise D, Pigneux A, Thomas X, Rigal-Huguet F, Lioure B, Auvrignon A, Fiere D, Reiffers J, Castaigne S, Leverger G, Harousseau JL, Socie G, Dombret H. 2002. A white blood cell index as the main prognostic factor in t(8;21) acute myeloid leukemia (AML): A survey of 161 cases from the French AML Intergroup. Blood 99:3517-3523.
23. Paschka P, Marcucci G, Ruppert AS, Mrozek K, Chen H, Kittles RA, Vukosavljevic T, Perrotti D, Vardiman JW, Carroll AJ, Kolitz JE, Larson RA, Bloomfield CD. 2006. Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv(16) and t(8;21): A Cancer and Leukemia Group B Study. J Clin Oncol 24:3904-3911.
24. Peterson LF, Boyapati A, Ahn EY, Biggs JR, Okumura AJ, Lo MC, Yan M, Zhang DE. 2007. Acute myeloid leukemia with the 8q22;21q22 translocation: Secondary mutational events and alternative t(8;21) transcripts. Blood 110:799-805.
25. Roche-LestienneC, Deluche L, Corm S, Tigaud I, Joha S, Philippe N, Geffroy S, Lai JL, Nicolini FE, Preudhomme C. 2008. RUNX1 DNA-binding mutations and RUNX1-PRDM16 cryptic fusions in BCR-ABL+ leukemias are frequently associated with secondary trisomy 21 and may contribute to clonal evolution and imatinib resistance. Blood 111:3735-3741.
26. Sarriera JE, Albitar M, Estrov Z, Gidel C, Aboul-Nasr R, Manshouri T, Kornblau S, Chang KS, Kantarjian H, Estey E. 2001. Comparison of outcome in acute myelogenous leukemia patients with translocation (8;21) found by standard cytogenetic analysis and patients with AML1/ETO fusion transcript found only by PCR testing. Leukemia 15:57-61.
27. Schlenk RF, Benner A, Krauter J, Buchner T, Sauerland C, Ehninger G, Schaich M, Mohr B, Niederwieser D, Krahl R, Pasold R, Dohner K, Ganser A, Dohner H, Heil G. 2004. Individual patient data-based meta-analysis of patients aged 16 to 60 years with core binding factor acute myeloid leukemia: A survey of the German Acute Myeloid Leukemia Intergroup. J Clin Oncol 22:3741-3750.
28. Schnittger S, Kohl TM, Haferlach T, Kern W, Hiddemann W, Spiekermann K, Schoch C. 2006. KIT-D816 mutations in AML1-ETO-positive AML are associated with impaired eventfree and overall survival. Blood 107:1791-1799.
29. Silva FP, Lind A, Brouwer-Mandema G, Valk PJ, Giphart-Gassler M. 2007. Trisomy 13 correlates with RUNX1 mutation and increased FLT3 expression in AML-M0 patients. Haematologica 92:1123-1126.
30. Sun X, Medeiros LJ, Lu D, Rassidakis GZ, Bueso-Ramos C. 2003. Dysplasia and high proliferation rate are common in acute myeloid leukemia with inv(16)(p13q22). Am J Clin Pathol 120:236-245.
31. Sun X, Zhang W, Ramdas L, Stivers DN, Jones DM, Kantarjian HM, Estey EH, Vadhan-Raj S, Medeiros LJ, Bueso-Ramos CE. 2007. Comparative analysis of genes regulated in acute myelomonocytic leukemia with and without inv(16)(p13q22) using microarray techniques, real-time PCR, immunohistochemistry, and flow cytometry immunophenotyping. Mod Pathol 20:811-820.
32. Swerdlow S, Campo E, Harris N, Jaffe E, Pileri S, Stein HT, Varidman J. 2008. WHO classi.cation of tumors of haematopoietic and lymphoid tissues. Lyon: International Agency for Research on Cancer.
33. Valbuena JR, Medeiros LJ, Rassidakis GZ, Hao S, Wu CD, Chen L, Lin P. 2006. Expression of B cell-specific activator protein/PAX5 in acute myeloid leukemia with t(8;21)(q22;q22). Am J Clin Pathol 126:235-240.
34. Verhaak RG, Wouters BJ, Erpelinck CA, Abbas S, Beverloo HB, Lugthart S, Lowenberg B, Delwel R, Valk PJ. 2009. Prediction of molecular subtypes in acute myeloid leukemia based on gene expression profiling. Haematologica 94:131-134.
35. Wang YY, Zhou GB, Yin T, Chen B, Shi JY, Liang WX, Jin XL, You JH, Yang G, Shen ZX, Chen J, Xiong SM, Chen GQ, Xu F, Liu YW, Chen Z, Chen SJ. 2005. AML1-ETO and C-KIT mutation/overexpression in t(8;21) leukemia: Implication in stepwise leukemogenesis and response to Gleevec. Proc Natl Acad Sci USA 102:1104-1109.
36. Yin CC, Medeiros LJ, Glassman AB, Lin P. 2004. t(8;21)(q22;q22) in blast phase of chronic myelogenous leukemia. Am J Clin Pathol 121:836-842.
37. Zhao W, Bueso-Ramos CE, Verstovsek S, Barkoh BA, Khitamy AA, Jones D. 2007. Quantitative profiling of codon 816 KIT mutations can aid in the classification of systemic mast cell disease. Leukemia 21:1574-1576.